Is aging written in your genes? RoC’s new skin longevity study measures the effects of Clinical Retinol on identical twins
RoC is recruiting at least 30 pairs of adult female identical twins, aged 40 and over and living in the U.S., for a 12-week study of a regimen with its Patented Clinical Retinol.
For the first time, RoC is pairing clinical skin measures with lifestyle data. Throughout the study, participants wear an Oura Ring, which tracks sleep, stress, heart rate, heart rate variability and temperature trends.
Each pair completes a baseline period before starting the 12-week regimen. Clinical assessments include expert grading, digital photography, corneometer readings and subject self-assessment.
Because identical twins share the same genetic blueprint, differences that emerge over the course of the study are less likely to be explained by genetics. The aim is to understand how much of long-term skin health comes from genes and how much from daily habits, and what role Clinical Retinol may play.
The study builds on a pilot clinical study of Clinical Retinol in identical twins. First results were presented at the American Academy of Dermatology (AAD) Annual Meeting in March 2026.
RoC is developing the protocol with input from its Longevity Council, a panel of experts in dermatology, aging biology and precision medicine.
Art Pellegrino, RoC’s Chief Scientific Officer, said that by pairing clinical skin measurements with real-world biometric data from Oura, RoC hopes to deepen its understanding of both the effects of Clinical Retinol and the broader forces that shape skin longevity. “Genetics sets the starting point; lifestyle draws the curve,” he said.
Results are expected in mid-2027. Twin pairs who want to take part can apply through rocskincare.com/pages/roc-twin-study-registration.
Read more: the full release on PR Newswire (October 27, 2026) and coverage in Longevity.Technology (November 5, 2026).



